News & Updates

Treatment with mirtazapine to improve severe breathlessness in patients with chronic obstructive pulmonary disease (COPD), interstitial lung diseases (ILD), or both falls flat, with the use of the medication even associated with adverse reactions, as shown in a phase III study.

New drug applications approved by US FDA as of 1-15 August 2024 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

In pregnant women with obstructive sleep apnoea (OSA), continuous positive airway pressure (CPAP) treatment helps lower the risk of gestational hypertension and pre-eclampsia, according to the results of a meta-analysis.

Rheumatoid arthritis (RA) appears to convey a 50-percent increase in the risk of lung cancer, with the risk increase even more pronounced for individuals with RA-interstitial lung disease (ILD), according to a study

Use of filgrastim among lung transplant recipients (LTRs) for the treatment of neutropenia contributes to an increased burden of acute cellular rejection (ACR) and a reduced time to ACR, but not to an increased likelihood of ACR at 6 months, a study has shown.

Treatment with cytisinicline for 12 weeks, in addition to behavioural support, is well tolerated and appears to help e-cigarette users to quit vaping, according to the results of the phase II ORCA-V1 trial.